BioInnovation Institute Funds 11 Life‑science Startups with €500k Convertible Loans Each

Why It Matters

BII’s coordinated financing and infrastructure accelerate the commercialization of high‑impact scientific breakthroughs, reinforcing Europe’s position in health, climate and quantum innovation. The influx of external capital demonstrates investor confidence in BII‑selected ventures and their market potential.

Key Takeaways

• Eleven startups receive €500k convertible loans each.
• BII's total portfolio now 142 firms, €145M funded.
• Cohort spans graphene, water, biotech, quantum, food tech.
• External investors contributed ~€1.1B to BII-backed companies.
• Recent €1.3M follow‑on funding supports five deep‑tech startups.

Pulse Analysis

BioInnovation Institute’s Venture Lab model blends capital with hands‑on resources, offering startups a €500,000 convertible loan that can later convert to equity once milestones are met. This structure reduces early‑stage risk while preserving upside for both founders and investors, a formula that has helped BII amass €145 million in direct funding across 142 companies. By coupling financial support with laboratory infrastructure and a curated mentor network, BII creates a low‑friction pathway from academic discovery to market‑ready product.

The latest cohort illustrates BII’s sector‑agnostic yet mission‑driven approach. Companies range from 2D’s scalable graphene platforms for sustainable manufacturing to Vasuqi’s light‑based water‑purification technology, and from Combotope Therapeutics’ tumour‑selective antibodies to QFactory’s custom quantum sensors. This diversity aligns with BII’s focus on human health, planetary health and quantum innovation, ensuring that breakthroughs address both medical needs and broader environmental challenges. The inclusion of food‑tech, such as Étiquette’s alcohol‑free wine, further underscores the institute’s commitment to circular, low‑impact solutions.

From a market perspective, BII’s ecosystem acts as a catalyst for larger capital inflows. Portfolio companies have already attracted about €1.1 billion from external investors, signaling strong confidence in the institute’s selection criteria. The recent €1.3 million follow‑on round for five deep‑tech firms highlights BII’s willingness to double‑down on promising ventures, accelerating product development and scaling. As Europe seeks to compete with U.S. and Asian deep‑tech hubs, BII’s blend of funding, facilities and network positions it as a pivotal engine for next‑generation biotech, climate, and quantum enterprises.

Deal Summary

Copenhagen‑based BioInnovation Institute announced that its Venture Lab programme will support 11 early‑stage life‑science startups, each receiving a €500,000 convertible loan and access to labs, mentorship and its investor network. The 12‑month programme aims to accelerate commercialization of technologies in human health, biotechnology and quantum sectors.